Product image of Oxaliplatin Hikma (Oxaliplatin) supplied by GNH India

Oxaliplatin Hikma

Active Ingredient:
Oxaliplatin
Origin:
EU

Oxaliplatin Hikma (Oxaliplatin)

Oxaliplatin, the active ingredient in Oxaliplatin Hikma, is a platinum‑based chemotherapy agent presented as a sterile powder for intravenous infusion use. It is employed in the treatment of colorectal cancer, typically in combination regimens for adult patients. GNH India supplies Oxaliplatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH India supplies Oxaliplatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA replication in gastrointestinal malignancies.

  • Colorectal cancer: used in adjuvant or metastatic settings to improve progression‑free survival.
  • Gastric cancer: combined with fluoropyrimidines for enhanced response rates.
  • Pancreatic cancer: part of multi‑drug regimens to increase tumor control.
  • Small‑cell lung cancer: employed in select protocols to augment cytotoxic effect.
  • Ovarian cancer: used off‑label within clinical trials to explore efficacy.
  • Esophageal cancer: incorporated in combination therapy for advanced disease.

How It Works

  • Oxaliplatin forms reactive platinum‑DNA adducts that cause intra‑ and inter‑strand cross‑links, disrupting DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells. Its activity is enhanced when combined with fluoropyrimidines, exploiting synergistic cytotoxic mechanisms.

Side Effects

Oxaliplatin may cause a range of adverse reactions, from mild to severe, requiring monitoring during therapy.

Common Side Effects

  • Nausea and vomiting: mild to moderate gastrointestinal upset.
  • Peripheral neuropathy: tingling or numbness, often dose‑related.
  • Diarrhea: watery stools that may require antidiarrheal support.
  • Fatigue: generalized tiredness affecting daily activities.
  • Thrombocytopenia: reduced platelet count increasing bleed risk.
  • Neutropenia: lowered neutrophil levels predisposing to infection.

Serious or Rare Side Effects

  • Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
  • Acute pulmonary toxicity: dyspnea or infiltrates on imaging.
  • Hemolytic‑uremic syndrome: rare renal and hematologic complication.
  • Cardiotoxicity: arrhythmias or myocardial injury.
  • Severe electrolyte disturbances: hypomagnesemia or hypokalemia.
  • Persistent neuropathy: long‑lasting sensory deficits after treatment.

Precautions & Warnings

Oxaliplatin requires careful assessment before and during treatment to minimize risks.

  • Renal function: assess creatinine clearance before initiation and monitor regularly.
  • Hepatic function: evaluate liver enzymes, especially in patients with metastasis.
  • Pre‑existing neuropathy: consider dose adjustments if baseline neuropathy is present.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risk.
  • Concomitant ototoxic drugs: monitor auditory function when used together.
  • Store at below 25°C: keep in original container, protect from moisture and light.

Avoid Interactions

Oxaliplatin can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics: increased risk of nephrotoxicity.
  • High‑dose vitamin C infusions: may reduce platinum‑DNA binding.
  • Live vaccines: immunosuppression may diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin, DOACs): heightened bleeding risk due to thrombocytopenia.
  • Antiemetics (5‑HT3 antagonists): may require dose adjustments for optimal control.
  • CYP450 inducers (rifampicin): potential alteration of drug clearance.
  • NSAIDs: increased risk of gastrointestinal irritation.
  • Diuretics: monitor electrolytes for additive hypomagnesemia.

Frequently Asked Questions

Oxaliplatin Hikma is a platinum‑based chemotherapy indicated for the treatment of colorectal cancer and other gastrointestinal malignancies, typically as part of combination regimens in adult patients.

Oxaliplatin creates platinum‑DNA adducts that cause cross‑linking of DNA strands, interrupting replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The specific dose and infusion schedule are determined by the prescribing oncologist based on the patient’s condition, body surface area, and treatment protocol.

Oxaliplatin is classified as contraindicated in pregnancy and breastfeeding unless the potential benefit justifies the risk, as it may cause fetal toxicity and is excreted in breast milk.

Submit an enquiry on the product page at gnhindia.com, providing the required quantity and institutional credentials. GNH India will verify eligibility, then respond with pricing, availability, shipping details and any necessary import documentation.

Oxaliplatin shares the DNA‑cross‑linking mechanism of cisplatin and carboplatin but has a distinct side‑effect profile, notably a higher incidence of peripheral neuropathy and lower nephrotoxicity, making it preferable for certain gastrointestinal cancers.

Store the product below 25 °C in its original packaging, protecting it from moisture and light. Reconstitute only with the recommended diluent and use within the time frame specified in the label.

Oxaliplatin is supplied as a sterile powder for intravenous infusion. It is reconstituted with a suitable diluent and administered by a healthcare professional over a prescribed infusion period, usually 2 hours.

Serious risks include severe hypersensitivity reactions, acute pulmonary toxicity, hemolytic‑uremic syndrome, cardiotoxicity, and persistent peripheral neuropathy that may be long‑lasting or irreversible.

Patients with known hypersensitivity to oxaliplatin or other platinum compounds, severe pre‑existing neuropathy, uncontrolled renal or hepatic impairment, and pregnant or breastfeeding women (unless benefits outweigh risks) should avoid this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Oxaliplatin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT